A truncated-dose regimen of daclizumab for prevention of acute rejection in kidney transplant recipients: A single-center experience

Transplantation

Volumn 78, Issue 10, 2004, Pages 1560-1563

  Soltero, Liliana ^a,c   Carbajal, Hector ^a   Sarkissian, Nadine ^b   Khan, Abdul Jabbar ^a   Brennan, Stephen ^a   Gonzalez, Juan M ^a   Truong, Luan D ^b,c   Suki, Wadi N ^a,c  

^a Kidney Institute   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Daclizumab; Dose; Graft rejection; Kidney transplantation; Monoclonal antibodies

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; COTRIMOXAZOLE; CYCLOSPORIN; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEPATITIS C; HERPES; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOFT TISSUE INFECTION;

ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 9244261029     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000140767.67868.F1     Document Type: Article

References (15)

1. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997; 63: 33.
2. Vincenti F, Pace D, Birnbaum J, et al. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003; 3: 50.
3. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161.
4. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110.
5. Ekberg H, Backman L, Tufveson G, et al. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation: No 14874. and No 14393 Zenapax Study Groups. Transplant Proc 1999; 31: 267.
6. Ahsan N, Holman MJ, Jarowenko MV, et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002; 2: 568.
7. Chang GJ, O'Rourke R, Lee I, et al. One or two doses of daclizumab provide effective immunosuppression for renal transplant patients with high immunologic risk or with delayed graft function. Transplantation 1999; 67: S149.
8. ter Meulen CG, Baan CC, Hene RJ, et al. Two doses of daclizumab are sufficient for prolonged interleukin-2R alpha chain blockade. Transplantation 2001; 72: 1709.
9. Millan M, Pavlakis M, Alfrey E, et al. A two-dose regimen of daclizumab (Zenapax) in high-risk renal transplant recipients. Transplantation 1999; 67: 584.
10. Stratta RJ, Alloway E, Hodge E, et al. A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis. Transplant Proc 2002; 34: 1903.
11. Ekberg N, Persson NH, Kallen R, et al. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Scand J Immunol 2003; 58: 670.
12. Niemeyer G, Koch M, Light S, et al. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002; 2: 454.
13. Rabago G, Manito N, Almenar L, et al. Induction therapy with two doses of daclizumab in heart transplantation: A prospective, multicentric clinical study. Interim analysis. J Heart Lung Transplant 2001; 22: S123.
14. Data on file, Hoffman-La Roche, Inc., Nutley, NJ.
15. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: Impact on chronic rejection. Transplantation 1993; 55: 993.